Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

ABSTRACT:

Context

Various molecular mechanisms play a role in the development of resistance to androgen deprivation therapy in castration-resistant prostate cancer (CRPC).

Objective

To understand the mechanisms and biological pathways associated with the progression of prostate cancer (PCa) under systemic androgen depletion or administration of the novel antiandrogens abiraterone, enzalutamide, and ARN-509. This review also examines the introduction of novel combinational approaches for patients with CRPC.

Evidence acquisition

PubMed was the data source. Keywords for the search were castrate resistant prostate cancer, abiraterone, enzalutamide resistance mechanisms, resistance to androgen deprivation, AR mutations, amplifications, splice variants, and AR alterations. Papers pub

SUBMITTER: Karantanos T 

PROVIDER: S-EPMC5301306 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature